Interim report January – June 2010

​

Transplantation sector operations in the second quarter

• OLERUP SSP’s sales growth in local currencies rose by 11 percent in the second quarter compared to the corresponding period last year. Sales in Europe rose by 3 percent and sales in North America were up 47 percent. Net sales in Swedish kronor amounted to SEK 19.8 million (20.0) in the second quarter.
• AbSorber and the U.S. sales company Olerup Inc. are included in full in the consolidated financial statements for the second quarter. The consolidated results are affected by costs related to the sales organization and marketing, which was not the case last year.
• AbSorber achieved great success with its product XM-ONE® at the leading center for transplantation matching in the U.S.

 Venture companies in the second quarter

• Positive results for AnaMar’s phase 1 trials
• Recopharma enters into an agreement with the U.S. biotech company Promosome
• Biovator’s test for type 1 allergenicity is presented at key international conference

 Key events after the period end

• BioResonator receives CE marking for ART™ – European launch begins
• AbSorber organizes a symposium at The Transplant Society’s annual congress

Consolidated financial performance January - June, 2010

• Net sales was SEK 41.5 million (43.0)
• Operating income(EBIT) was SEK 3.9 million (13.2)
• Net loss after tax was SEK 0.1 million (+7.7)
• Results of investing activities SEK 0.0 million (0.0)
• Earnings per share, basic and diluted was SEK 0.08 (0.59)
• Equity per share was SEK 34.19 (37.11)
• Equity/assets ratio was 68 percent (74)

Commentary from CEO Ingemar Lagerlöf on the second quarter 2010:
“More than two years have passed since we acquired Olerup SSP in order to build a focused business in the transplantation sector together with our company AbSorber. Investments in the sales and marketing organization are already beginning to show results for Olerup SSP, with an increase in sales of 47 percent in the U.S. market in the second quarter compared to the same period last year. We are now stepping up efforts in the transplantation sector company, primarily through organic growth but also through acquisition of companies and complementary products."

For more information please contact:
Ingemar Lagerlöf, CEO, cell +46 (0)70-873 2733 or email ingemar.lagerlof@linkmed.se
Okee Williams, Portfolio Manager, cell +46 (0)70- 600 5364 or email okee.williams@linkmed.se

LinkMed develops life science companies in collaboration with innovators and other financiers. LinkMed has two business areas, a commercial transplantation sector business with two subsidiaries and a venture portfolio comprising life science companies. The venture companies, all of which are associated companies, consist of four companies in drug development and biotechnology and six companies in diagnostics and medical technology. LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap section (ticker: LMED).

Tags: